COVACTA trial raises questions about tocilizumab's benefit in COVID-19
- PMID: 32929415
- PMCID: PMC7480990
- DOI: 10.1016/S2665-9913(20)30313-1
COVACTA trial raises questions about tocilizumab's benefit in COVID-19
Comment in
-
High-stakes heterogeneity in COVID-19.Lancet Rheumatol. 2020 Oct;2(10):e577. doi: 10.1016/S2665-9913(20)30310-6. Epub 2020 Sep 23. Lancet Rheumatol. 2020. PMID: 32989434 Free PMC article. No abstract available.
LinkOut - more resources
Full Text Sources